Association Between FCGR3A V158F Polymorphism and Response to Rituximab-Based Therapy in Patients With Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-analysis

Three short Zenodo descriptions, one per file: Table 1. Characteristics of Included Studies and Response Data by FCGR3A Genotype Supplementary data file (Excel format) accompanying the systematic review and meta-analysis "Association Between FCGR3A V158F Polymorphism and Response to Rituximab-Based Therapy in Patients With Diffuse Large B-Cell Lymphoma." Contains study-level characteristics (author, year, region, design) and response outcomes (responders, non-responders, totals) stratified by FCGR3A V158F genotype (VV vs. VF+FF) for the eight studies included in the quantitative synthesis (N = 715 patients). Underlies the pooled odds ratio analysis reported in the main manuscript. JASP Inputs Raw data file used as input for the meta-analytic calculations performed in JASP (Version 0.18.3; University of Amsterdam), accompanying the systematic review and meta-analysis on FCGR3A V158F polymorphism and rituximab response in diffuse large B-cell lymphoma. Contains study-level genotype and response counts (recessive model: VV vs. VF+FF) for the eight included studies, formatted for direct import into the JASP meta-analysis module. Underlies the pooled effect size, heterogeneity, sensitivity, and publication bias analyses reported in the manuscript. Screening Sheet Study screening and selection record accompanying the systematic review and meta-analysis on FCGR3A V158F polymorphism and rituximab response in diffuse large B-cell lymphoma. Documents the title/abstract and full-text screening process conducted by two independent reviewers in accordance with PRISMA 2020 guidelines, including inclusion/exclusion decisions and reasons for exclusion at the full-text stage. Supports the PRISMA flow diagram (Figure 1) reported in the main manuscript.